VA-INTELSAT
12.4.2022 15:02:09 CEST | Business Wire | Press release
Intelsat — operator of the world’s largest integrated satellite and terrestrial network and a leading provider of inflight connectivity (IFC) — today announced its latest service offering: Cloud Connect Media, a connectivity solution that provides programmers with secure access between the IntelsatOne Media Network and Amazon Web Services (AWS).
Cloud Connect Media is designed to provide content providers with a private, dedicated secure gateway between AWS and the Intelsat global media distribution network. Intelsat is an AWS Select Partner in the AWS Partner Network (APN).
This collaboration can provide Intelsat media customers a more efficient way to connect to their playout, video editing, and additional resources they use in the cloud while still accessing the IntelsatOne media network for centralized distribution and managed services, including uplink and/or downlink to key satellites and teleports, colocation, and much more.
C-SPAN, the nonprofit, public affairs network providing Americans with unfiltered access to federal government proceedings, will be the first Intelsat customer to use Cloud Connect Media to add resiliency and reliability to their linear workflows. C-SPAN and Intelsat have been longstanding partners driving innovation in the media industry, and this trend continues with Cloud Connect Media.
“Intelsat's rollout of Cloud Connect Media helps complete C-SPAN’s transition to a total cloud configuration by providing a fast and reliable path from our uplink location directly to Amazon Web Services, with the most up-to-date connectivity available,” said Roxane Kerr, vice president of Technology for C-SPAN.
“The ability to send and receive media content securely from the cloud, while maintaining broadcast-grade distribution reliability, has become a focus for many of our media customers,” said Bill O’Hara, vice president and general manager of Media Business at Intelsat. “Cloud Connect Media uses AWS to help our customers access their cloud services while still being able to utilize the industry-leading Intelsat network and our full suite of media managed services for regional and global video distribution.”
In addition to advancing media services, Intelsat customers using enterprise and commercial aviation connectivity services who also require dedicated secure connectivity to their cloud-based services will be able to take advantage of AWS Direct Connect.
“AWS Direct Connect can support Intelsat’s mission with a low latency, secure, and private connection to the global AWS network,” said Clint Crosier, director, Aerospace and Satellite at AWS. “The speed and agility of AWS are well suited to help Intelsat meet customer expectations for rapid, reliable global connectivity and communication.”
Cloud Connect Media expands the capabilities of Intelsat’s Cloud Connect, launched in 2020 with secure cloud connectivity available to customers of the global FlexEnterprise network. As organizations continue to integrate cloud-based services into their operations, the Cloud Connect portfolio will aggregate the capabilities of cloud partners and Intelsat’s global networks to enable new services and extend the benefits and reach of the cloud to locations around the globe.
Cloud Connect Media is currently available in the United States and Europe.
About Intelsat
As the foundational architects of satellite technology, Intelsat operates the world’s most trusted satellite telecom network. We apply our unparalleled expertise and global scale to connect people, businesses and communities, no matter how difficult the challenge. Intelsat is building the future of global communications with the world’s first hybrid, multi-orbit, software-defined 5G network designed for simple, seamless, and secure coverage precisely when and where our customers most need it. Follow the leader in global connectivity and “Imagine Here,” with us, at Intelsat.com
.
Follow Us on Social Media:
Twitter
| LinkedIn
| Facebook
| Instagram
| YouTube
View source version on businesswire.com: https://www.businesswire.com/news/home/20220412005361/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom